The Patent Finder

Terms ending in 2040

Actelion Pharmaceuticals Ltd

Every in-force patent on Actelion Pharmaceuticals Ltd's record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,612,600Pharmaceutical Composition Comprising Macitentan for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
In force
 · Low confidence
Actelion Pharmaceuticals Ltd.In forceLow confidence
US 12,121,516Pharmaceutical Composition Comprising Selexipag
In force
 · High confidence
Actelion Pharmaceuticals Ltd.In forceHigh confidence
2 of 2 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited